Novartis gets an approval for Reclast (bone disease). This drug is also being positioned for once-a-year treatment for osteoporosis.
But Prexige’s future is still cloudy, given the negative FDA assessment of Merck’s Arcoxia.
Back to osteoporosis – new two-tablets monthly dosage for Actonel approved.
Is there anything statins don’t do?
Avalide (BMS and Sanofi-Aventis) gets a positive vote for earlier use in hypertension.
The Pharma image problem – a summary from the Pharmalot blog.
Herceptin-Plus on the horizon for cancer treatment?
Interesting interview with Centocor’s CEO, including his take on pharmaceutical selling.